Alamar Biosciences Launches NULISAseq™ Neuro 220 Panel, its largest precision proteomics panel with the sensitivity and specificity to advance neurological disease research

Core Insights - Alamar Biosciences has launched the NULISAseq Neuro 220 Panel, which allows for the multiplexed measurement of 220 biomarkers from a single sample, enhancing early detection capabilities for neurodegenerative diseases [1][2] Group 1: Product Launch and Features - The NULISAseq Neuro 220 Panel expands on the existing NULISAseq CNS Disease Panel 120, incorporating new biomarkers developed with support from The Michael J. Fox Foundation for Parkinson's Research [1][2] - The panel includes a comprehensive collection of Tau protein assays, targeting both brain-derived and peripheral isoforms, making it the largest suite of Tau assays available in a single panel [1][2] - The panel is designed for ultra-high sensitivity and high specificity, ensuring compatibility with non-invasive sample collection devices and supporting pre-symptomatic detection [2][4] Group 2: Research and Development Impact - The launch of the NULISAseq Neuro 220 Panel is expected to raise the standard for neurodegenerative disease research, applicable to a wide range of conditions including Alzheimer's, Parkinson's, and multiple sclerosis [2][4] - The panel facilitates the analysis of disease heterogeneity, detection of co-pathologies, and identification of prognostic or therapeutic response signatures across clinical cohorts [2][4] Group 3: Conference Presentation - The NULISAseq Neuro 220 Panel will be featured at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD 2026) in Copenhagen, Denmark, with data presentations scheduled [3][4] - Dr. Henrik Zetterberg will present data demonstrating the utility of the panel in neurodegenerative diseases during Alamar's product theater on March 18 [3]